Jefferies Financial Group Reaffirms "Hold" Rating for Chimerix (NASDAQ:CMRX)

Jefferies Financial Group reiterated their hold rating on shares of Chimerix (NASDAQ:CMRX - Free Report) in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has a $8.50 price objective on the biopharmaceutical company's stock, down from their previous price objective of $10.00.

A number of other analysts also recently weighed in on CMRX. Wedbush restated a "neutral" rating and issued a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research report on Wednesday. HC Wainwright restated a "neutral" rating and issued a $8.55 price objective (down from $11.00) on shares of Chimerix in a report on Wednesday.

Chimerix Price Performance

CMRX stock remained flat at $8.43 during mid-day trading on Wednesday. The company's stock had a trading volume of 7,018,814 shares, compared to its average volume of 2,030,837. The firm's 50 day simple moving average is $4.24 and its two-hundred day simple moving average is $2.26. Chimerix has a 52-week low of $0.75 and a 52-week high of $8.47. The company has a market cap of $758.16 million, a PE ratio of -8.97 and a beta of 0.32.

Insider Buying and Selling

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares of the company's stock, valued at $2,755,405.56. This represents a 1.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 20,760 shares of company stock worth $91,175 in the last ninety days. 13.10% of the stock is owned by insiders.

Remove Ads

Hedge Funds Weigh In On Chimerix

Hedge funds have recently modified their holdings of the company. Deerfield Management Company L.P. Series C bought a new stake in shares of Chimerix in the fourth quarter worth about $13,124,000. Rosalind Advisors Inc. purchased a new stake in Chimerix in the 4th quarter worth approximately $10,614,000. Millennium Management LLC grew its position in shares of Chimerix by 6.8% in the 4th quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company's stock worth $8,900,000 after buying an additional 161,795 shares during the last quarter. Marshall Wace LLP grew its position in shares of Chimerix by 1,318.5% in the 4th quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company's stock worth $7,705,000 after buying an additional 2,057,864 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new position in shares of Chimerix during the fourth quarter valued at approximately $7,169,000. Hedge funds and other institutional investors own 45.42% of the company's stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.